Men considering testosterone therapy often have questions about prostate effects. Testosterone itself plays a limited direct role, but its conversion to dihydrotestosterone (DHT) is central to prostate tissue activity. Understanding this process, potential growth patterns, PSA monitoring, and other DHT-related effects helps you make informed decisions based on available data.
How Testosterone Converts to DHT and Its Role in the Prostate
Testosterone is converted to DHT by the enzyme 5-alpha reductase, which is highly active in prostate tissue. DHT binds more strongly to androgen receptors than testosterone, driving cell proliferation in the prostate gland. In normal development, this supports growth, but with age or therapy, it can contribute to benign prostatic hyperplasia (BPH)—non-cancerous enlargement that may affect urinary flow.
Human studies show intraprostatic DHT levels are similar in normal and BPH tissue when measured properly, but DHT remains a key driver of growth. Testosterone therapy can modestly increase prostate volume in some men (around 12% in certain trials), primarily through this DHT pathway.
The Ins and Outs of Prostate Growth
Prostate growth with androgens involves a balance between cell multiplication and cell death. DHT tips this toward proliferation in susceptible tissue. Not every man on therapy experiences significant enlargement—factors like age, genetics, and baseline prostate size matter. Some research finds no major prostate volume increase with DHT treatment over 24 months in healthy older men, while other data link higher androgen activity to BPH symptoms. Therapy does not appear to raise prostate cancer risk in properly screened men, but regular evaluation is standard.
Using PSA as a Marker
Prostate-specific antigen (PSA) is a protein produced by prostate cells. Levels can rise with therapy due to increased gland activity or volume, even without cancer. Guidelines recommend baseline PSA before starting testosterone, followed by periodic checks. A significant rise may prompt further evaluation like digital rectal exam or imaging. PSA is a useful tool for tracking changes but is not perfect—it can be influenced by BPH, infection, or other factors. Consistent monitoring helps distinguish normal therapy-related shifts from issues needing attention.
Other Effects of DHT in the Body
DHT influences tissues beyond the prostate. In the scalp, it binds to hair follicle receptors in genetically prone men, shortening the growth cycle and causing miniaturization—leading to male pattern hair loss. On the skin, higher DHT activity increases oil production and can worsen acne by affecting sebaceous glands. These effects vary widely; some men on therapy notice accelerated thinning or breakouts if DHT rises, while others see minimal or no change. Management options include dose adjustments or targeted blockers when appropriate.
Practical Takeaways for Therapy Users
Frequent lab monitoring and symptom tracking allow adjustments to keep levels in a range that delivers benefits with fewer unwanted effects. Discuss prostate family history and baseline screening with your provider before and during treatment.
For men navigating testosterone therapy or exploring supportive options like peptides for balanced hormone management, services available through Vita Bella offer access to providers who review labs and tailor plans.
References
Welén K, Damber JE. Androgens, aging, and prostate health. Curr Opin Endocr Metab Res. 2022;27:100400. doi:10.1016/j.coemr.2022.100400.
Bui HN, Strugnell SA, et al. Intraprostatic testosterone and dihydrotestosterone. Part I. BJU Int. 2012;109(2):176-182. (Adapted from review data).
Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Urol Clin North Am. 2015;42(2):119-125. doi:10.1016/j.ucl.2014.12.006.
Urysiak-Czubatka I, Kmieć ML, Broniarczyk-Dyła G. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia and hirsutism. Postepy Dermatol Alergol. 2014;31(4):207-215. doi:10.5114/pdia.2014.44003.
